Robert J. Israel - Concepedia

Author

Robert J. Israel

Progenics Pharmaceuticals (United States)ORCID

Also Known As

R ISRAEL, R Israel, R J Israel, R. Israel, R. J. ISRAEL, R. J. Israel, R.J. Israel, Robert Israel, Robert J Israel, Robert J. Israel

133

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Progenics Pharmaceuticals (United States)Virginia Oncology Associates Carolina Urologic Research Center Comprehensive Cancer Centers of Nevada Yale University

About

Robert J. Israel is an author at Progenics Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	17	1K
2	Health Sciences	6	6	466
3	Engineering	1	1	28
4	Public Health	1	1	12
5	Allergy	1	1	103

Robert J. Israel

Publications

Citations

H-Index

Page 1

	Year	Citations
Dehydroascorbic acid, a blood–brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke Judy Huang, David B. Agus, Christopher J. Winfree, Proceedings of the National Academy of Sciences	2001	225
Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Russell K. Portenoy, Michele L. Moehl Boatwright, Diep N. H. Tran, Journal of Pain and Symptom Management Pain MedicinePostoperative Pain ManagementPharmacologyAddiction MedicineParallel Group	2008	181
Single‐Dose Safety, Pharmacology, and Antiviral Activity of the Human Immunodeficiency Virus (HIV) Type 1 Entry Inhibitor PRO 542 in HIV‐Infected Adults Jeffrey M. Jacobson, Israel Lowy, Courtney V. Fletcher, The Journal of Infectious Diseases Single‐dose SafetyImmunologyPharmacotherapyAntiviral DrugHuman Immunodeficiency Virus	2000	152
Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542 Jeffrey M. Jacobson, Robert J. Israel, Israel Lowy, Antimicrobial Agents and Chemotherapy Viral Entry InhibitorsHuman RetrovirusImmunologyPharmacologyHiv-1 Disease Progression	2004	123
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Paul B. Chapman, Donna M. Morrissey, Katherine S. Panageas, PubMed ImmunologyPathologyImmunotherapyTumor ImmunologyTumor Immunity	2000	103
Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in Humans Chun‐Su Yuan, Harold D. Doshan, Martha R. Charney, The Journal of Clinical Pharmacology Opioid EpidemicSteady StateHealthy SubjectsHealth SciencesGastrointestinal Pharmacology	2005	85
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer Susan F. Slovin, Marissa Kehoe, Robert J. Durso, Vaccine VaccinationUrologyMedicineImmunologyTherapeutic Vaccine	2012	83
Methylnaltrexone Treatment of Opioid-Induced Constipation in Patients with Advanced Illness Bruce Chamberlain, Karen L. Cross, Jaron L. Winston, Journal of Pain and Symptom Management Functional Gastrointestinal DisorderPain MedicineAddictionMedicineGastroenterology	2009	82
Recombinant CD4‐IgG2 in Human Immunodeficiency Virus Type 1–Infected Children: Phase 1/2 Study William T. Shearer, Robert J. Israel, Stuart E. Starr, The Journal of Infectious Diseases	2000	82
Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome Anthony A. Fodor, Mark Pimentel, William D. Chey, Gut Microbes Taxa Relative AbundanceDysbiosisGastroenterologyGut MicrobiotaDrug Resistance	2018	82

Page 1